Vera Therapeutics, Inc. (VERA) Cash Flow Statement
Vera Therapeutics, Inc. (VERA) generated -$338.7M of operating cash flow over the twelve months to 2026-06-30, spent $522000 on capital expenditure and had free cash flow of -$339.2M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
VERAVera Therapeutics, Inc.Follow VERA — free
—
Price chart with a free account
- Market cap
- 2.0B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 3 Nov, in 10 days
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -23.7 | -67.6 | -92.2 | -134.7 | -241.1 | -338.7 | |
| Capital expenditure | 0.0 | 0.1 | 0.1 | 1.0 | 0.6 | -0.5 | |
| Free cash flow | -23.7 | -67.7 | -92.2 | -135.7 | -241.7 | -339.2 | |
| Share repurchases | — | — | 0.0 | 0.0 | 0.0 | — | |
| Stock-based compensation | 3.0 | 8.9 | 11.5 | 20.8 | 37.9 | — |
USD millions · SEC XBRL
Vera Therapeutics, Inc. — questions
- What is Vera Therapeutics, Inc.'s operating cash flow?
- -$338.7M over the twelve months to 2026-06-30.
- How much does Vera Therapeutics, Inc. spend on capital expenditure?
- $522000 over the twelve months to 2026-06-30.
- What is Vera Therapeutics, Inc.'s free cash flow?
- -$339.2M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Vera Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.